ORBi: Foidart Jean-Michel - Maternal plasma soluble endoglin at 11-13 weeks's gestation in pre-eclampsia

Reference : Maternal plasma soluble endoglin at 11-13 weeks's gestation in pre-eclampsia


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Reproductive medicine (gynecology, andrology, obstetrics)
	To cite this reference:	http://hdl.handle.net/2268/63563

Title :	Maternal plasma soluble endoglin at 11-13 weeks's gestation in pre-eclampsia
Language :	English
Author, co-author :	Foidart, Jean-Michel [Université de Liège - ULg > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement >]
	Munaut, Carine [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
	Chantraine, Frédéric [Université de Liège - ULg > > Gynécologie-Obstétrique CHR >]
	Akolekar, R. [> >]
	Nicolaides, K. H. [> >]
Publication date :	2010
Journal title :	Ultrasound in Obstetrics & Gynecology
Publisher :	John Wiley & Sons Ltd.
Volume :	35
Issue/season :	6
Pages :	680-7
Audience :	International
ISSN :	0960-7692
e-ISSN :	1469-0705
City :	Chichester
Country :	United Kingdom
Keywords :	[en] Soluble endoglin ; Placental growth factor ; Uterine artery Doppler ; First-trimester screening ; Preeclampsia
Abstract :	[en] Objectives: To examine the performance of screening for preeclampsia (PE) by a combination of maternal factors, soluble endoglin (sEng), pregnancy associated plasma protein A (PAPP-A), placental growth factor (PlGF) and uterine artery lowest pulsatibility index (L-PI) at 11-13 weeks of gestation. Methods: Uterine artery L-PI, sEng, PAPP-A and PlGF were measured at 11-13 weeks in 90 singleton pregnancies that subsequently developed PE, including 30 that required delivery before 34 weeks (early-PE) and 60 with late-PE, and 180 unaffected controls. Screening performance for PE by maternal factors, sEng, PAPP-A, PlGF and uterine artery L-PI and their combinations was determined. Results: In early-PE, compared to controls, plasma sEng and uterine L-PI were significantly increased and serum PAPP-A and PlGF were decreased. In late-PE, compared to controls, serum PlGF was decreased and uterine L-PI was increased but plasma sEng and serum PAPP-A were not significantly different. In screening for early-PE, the detection rate at a 10% false positive rate was 46.7% for sEng alone and 96.3% for a combination of maternal factors, sEng, PlGF and uterine artery L-PI. Conclusions: Effective screening for early-PE can be provided by a combination of maternal factors, sEng, PlGF and uterine artery L-PI at 11-13 weeks.
Permalink :	http://hdl.handle.net/2268/63563
DOI :	10.1002/uog.7621

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	Foidart JM Ul Ob Gy 2010.pdf		Publisher postprint	91.68 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5